Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TissueGene-C in degenerative arthritis
NCT01825811Phase 2Completed
- Sponsor
- Kolon Life Science Inc.
- Start
- Oct 2012
- Primary completion
- Apr 2014
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Invossa in knee osteoarthritis (OA) (2 arms), sponsored by Kolon Life Science Inc. Primary endpoint: International Knee Documentation Committee Subjective Knee Evaluation at 48 weeks. Started Oct 2012; status: completed.
02
Drugs
Invossa
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01825811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01825811.